{
    "name": "Acamprosate",
    "genericName": "Campral",
    "tags": [
        "GABA modulator",
        "alcohol use disorder"
    ],
    "dosing": {
        "adult_acute": "666 mg TID (≥60 kg); 333-666 mg TID (<60 kg)",
        "adult_maintenance": "666 mg three times daily",
        "notes": "Take with meals. Begin after alcohol withdrawal is complete. Does not treat withdrawal symptoms. Works best in patients with goal of abstinence. Continue for up to 1 year.",
        "canadian_clinical": {
            "starting_dose": "666 mg TID (≥60kg); reduce to 333-666 mg TID if <60 kg.",
            "titration_schedule": "No titration; start at full dose after detoxification is complete.",
            "inpatient_strategy": "Initiate after acute alcohol withdrawal managed. Start full dose prior to discharge.",
            "outpatient_strategy": "Initiate when abstinence achieved. Combine with behavioral therapy. Follow up monthly initially.",
            "max_dose_evidence": "1998 mg/day (666 mg TID)",
            "max_dose_practice": "1998 mg/day."
        }
    },
    "cautions": {
        "renal": "Reduce dose if CrCl 30-50: 333 mg TID. Contraindicated if CrCl <30.",
        "hepatic": "No dose adjustment required — not significantly hepatically metabolized.",
        "pregnancy": "Avoid — insufficient safety data."
    },
    "warnings": [
        "Diarrhea (most common side effect)",
        "Suicidal ideation reported — monitor mental health",
        "Nausea, flatulence",
        "Not effective during active drinking — used for maintaining abstinence",
        "No abuse potential"
    ],
    "citations": [
        "CANMAT Substance Use Disorders 2019",
        "NICE Alcohol Use Disorder NG115 2019",
        "ASAM Clinical Practice Guidelines 2015"
    ]
}
